Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) pose substantial global health challenges. The growing concern in the scientific community regarding their association has spurred numerous studies, revealing a robust link in clinical investigations. Despite increasing evidence, the precise mechanistic interplay remains elusive. This review navigates the intricate relationship between MASLD and CKD, spotlighting their worldwide prevalence and shared risk factors. Population-based studies and meta-analyses underscore a significant association, heightening CKD risk in those with MASLD. Pathogenic factors such as lipotoxicity, insulin resistance, oxidative stress, and gut microbiota alterations contribute to both conditions. Acknowledging strengths and limitations of current evidence, the review underscores the necessity for longitudinal studies. Clinical implications encompass early detection, risk stratification, and monitoring, with interventions emphasizing lifestyle modifications and medications targeting shared risk factors. Novel therapies, including melatonin supplementation and modulation of the gut microbiome, are explored. This comprehensive review offers crucial insights into the intertwined nature of MASLD and CKD, guiding clinical practices and shaping future research directions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies

  • 期刊论文

  • 发表日期：

    2025年5月22日

查看全文
  • Kexin Lian,
  • Qiming Fan,
  • Sufang Sheng,
  • Kexin Zhang,
  • Xiaodong Sun,
  • Chengxia Kan,
  • Ruiyan Pan,
  • Zhentao Guo

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) pose substantial global health challenges. The growing concern in the scientific community regarding their association has spurred numerous studies, revealing a robust link in clinical investigations. Despite increasing evidence, the precise mechanistic interplay remains elusive. This review navigates the intricate relationship between MASLD and CKD, spotlighting their worldwide prevalence and shared risk factors. Population-based studies and meta-analyses underscore a significant association, heightening CKD risk in those with MASLD. Pathogenic factors such as lipotoxicity, insulin resistance, oxidative stress, and gut microbiota alterations contribute to both conditions. Acknowledging strengths and limitations of current evidence, the review underscores the necessity for longitudinal studies. Clinical implications encompass early detection, risk stratification, and monitoring, with interventions emphasizing lifestyle modifications and medications targeting shared risk factors. Novel therapies, including melatonin supplementation and modulation of the gut microbiome, are explored. This comprehensive review offers crucial insights into the intertwined nature of MASLD and CKD, guiding clinical practices and shaping future research directions.